Background and Aims Thoracic endovascular aortic repair (TEVAR) has become the first-line treatment for type B aortic dissection. Maximizing the aortic dissection coverage and promoting aortic remodeling without increasing the risk of paraplegia has become challenging in clinical practice. Here, the authors report the first case of clinical implantation of the new Talos distal perforating stent (Talos stent) in our country successfully performed in Xiangya Hospital of Central South University after its market release and analyze the related problems.Methods The clinical data of the first case of implantation of Talos Stent in China after its introduction to the market were reported. The advantages and disadvantages of this type of stent were analyzed and reviewed with a literature review.Results A 72-year-old male patient with Stanford type B aortic dissection requiring a long-length stent due to the extensive involvement of the aortic dissection underwent TEVAR with the newly-marketed novel Talos stent with the approval of himself and his family. The stent was easily guided towards the lesion during operation with precise positioning. After stenting, the aortic tears of the patient were thoroughly repaired, the false lumens were thrombosed entirely, and the distal intercostal perforating branches were preserved intact, with no development of aortic-related adverse events.Conclusion The Talos stent has excellent procedural performance, its long body ensures to the maximum extent possible the repair of aortic dissection and promotes aortic remodeling, and the distal perforation design can repair the aortic tears and preserve intercostal branches at the same time, and thereby prevent paraplegia caused by spinal cord ischemia.